Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
- The primary objective of this trial is to compare the dose-ranging pharmacodynamic
effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on
gastrointestinal transit in patients with C-IBS.
- The secondary objectives of this trial are:
1. To compare the dose ranging pharmacodynamic effects of placebo, and 100 and 1000 ug
MD-1100 Acetate once daily on time to first bowel movement after first drug intake.
2. To describe and summarize the effects of placebo, and 100 and 1000 ug MD-1100
Acetate once daily on stool frequency, stool consistency, ease of passage and
sensation of incomplete evacuation during the Treatment Period relative to
Baseline.